|Recombinant Human VTN protein (Catalog#10424-H07H)|
|0.2 μm filtered solution in PBS with 5% trehalose|
|This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human Vitronectin (rh Vitronectin; Catalog#10424-H07H; NP_000629.3; Asp 20-Leu 478). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography .|
ELISA: 0.5-1 μg/mL
This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human vitronectin. The detection limit for Human vitronectin is approximately 0.039 ng/well.
ELISA(Cap): 0.5-4 µg/ml
This antibody will detect Human Vitronectin / VTN in ELISA pair set (Catalog: # SEK10424). In a sandwich ELISA, it can be used as capture antibody when paired with (Catalog: # 10424-MM03).
Vitronectin, also known as VTN, is a member of the pexin family. It is an abundant glycoprotein found in serum the extracellular matrix and promotes cell adhesion and spreading. Vitronectin is a secreted protein and exists in either a single chain form or a cleaved, two chain form held together by a disulfide bond. Vitronectin is a plasma glycoprotein implicated as a regulator of diverse physiological process, including blood coagulation, fibrinolysis, pericellular proteolysis, complement dependent immune responses, and cell attachment and spreading. Because of its ability to bind platelet glycoproteins and mediate platelet adhesion and aggregation at sites of vascular injury, vitronectin has become an important mediator in the pathogenesis of coronary atherosclerosis. As a multifunctional protein with a multiple binding domain, Vitronectin interacts with a variety of plasma and cell proteins. Vitronectin binds multiple ligands, including the soluble vitronectin receptor. It may be an independent predictor of adverse cardiovascular outcomes following acute stenting. Accordingly, Vitronectin is suggested to be involved in hemostasis, cell migration, as well as tumor malignancy.